These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Pancreatitis following vaccination against measles, mumps, and rubella in a young adult]. Ramis Pedromingo M; Cañete Díaz A; Torres Rubio J; Magro Rodríguez R Aten Primaria; 1993 Feb; 11(2):105. PubMed ID: 8452988 [No Abstract] [Full Text] [Related]
43. Adverse reactions and mumps, measles and rubella vaccine. Benjamin CM; Silman AJ J Public Health Med; 1991 Feb; 13(1):32-4. PubMed ID: 2029434 [No Abstract] [Full Text] [Related]
44. Measles revaccination--an additional note. Med Lett Drugs Ther; 1989 Sep; 31(801):88. PubMed ID: 2642269 [No Abstract] [Full Text] [Related]
45. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Miller E; Goldacre M; Pugh S; Colville A; Farrington P; Flower A; Nash J; MacFarlane L; Tettmar R Lancet; 1993 Apr; 341(8851):979-82. PubMed ID: 8096942 [TBL] [Abstract][Full Text] [Related]
47. The introduction of measles/mumps/rubella vaccine. Midwife Health Visit Community Nurse; 1988 Sep; 24(9):358-9. PubMed ID: 3205172 [No Abstract] [Full Text] [Related]
48. Withdrawal of a mumps vaccine: reasons and impacts. Schmitt HJ; Just M; Neiss A Eur J Pediatr; 1993 May; 152(5):387-8. PubMed ID: 8319700 [No Abstract] [Full Text] [Related]
49. Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. Dourado I; Cunha S; Teixeira MG; Farrington CP; Melo A; Lucena R; Barreto ML Am J Epidemiol; 2000 Mar; 151(5):524-30. PubMed ID: 10707922 [TBL] [Abstract][Full Text] [Related]
50. Clinical and epidemiologic features of mumps meningoencephalitis and possible vaccine-related disease. McDonald JC; Moore DL; Quennec P Pediatr Infect Dis J; 1989 Nov; 8(11):751-5. PubMed ID: 2594449 [TBL] [Abstract][Full Text] [Related]
51. A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Edees S; Pullan CR; Hull D Public Health; 1991 Mar; 105(2):91-7. PubMed ID: 2068243 [TBL] [Abstract][Full Text] [Related]
53. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children. Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276 [TBL] [Abstract][Full Text] [Related]
54. Guillain-Barré syndrome after measles, mumps, and rubella vaccine. Rees J; Hughes R Lancet; 1994 Mar; 343(8899):733. PubMed ID: 7907701 [No Abstract] [Full Text] [Related]
58. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells. Just M; Berger R; Glück R; Wegmann A Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399 [TBL] [Abstract][Full Text] [Related]
59. Families win support for vaccine compensation claim. Dyer C BMJ; 1994 Sep; 309(6957):759. PubMed ID: 7950555 [No Abstract] [Full Text] [Related]
60. Autism and measles, mumps, and rubella vaccine. Altmann D Lancet; 2000 Jan; 355(9201):409-10. PubMed ID: 10665582 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]